Biologics accounted for 38% of prescription drug spending in the United States in 2015 [1] and are often called the single largest driver of drug spending growth. So the introduction of biosimilars created a great deal of excitement, as they represent an opportunity to lower costs for both patients and payers. However, their entry to the market has been met with numerous challenges—even leading some to question their potential to meaningfully inflect prices.
Create your free account to access 2 resources each month, including the latest research and webinars.
You have 2 free members-only resources remaining this month remaining this month.
1 free members-only resources remaining this month
1 free members-only resources remaining this month
Never miss out on the latest innovative health care content tailored to you.